Evidence map›Paper›PMID 36810141›Full record

ArticleActa veterinaria Scandinavica2023

Cutaneous protothecosis in a dog successfully treated with oral itraconazole in pulse dosing.

Vanessa Cunningham Gmyterco, Tomasz Jagielski, Gustavo Baldasso, Louise Helene Bacher, Márcio Garcia Ribeiro, Marconi Rodrigues de Farias

Erratum issuedOpen access · goldAbstract readCase Reports
In one paragraph

Article in Acta veterinaria Scandinavica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Protothecosis in Dogs: A Narrative Review.Journal of veterinary internal medicine
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Vanessa Cunningham GmytercoDepartment of Veterinary Medicine, School of Life and Sciences, Pontifícia Universidade Católica do Paraná, 1155 Imaculada Conceição Street, Curitiba, PR, 80215-901, Brazil. vanessagmyterco@gmail.com.ORCID http://orcid.org/0000-0001-9102-1066
Tomasz JagielskiDepartment of Medical Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw, I. Miecznikowa 1, 02-096, Warsaw, Poland. t.jagielski@uw.edu.pl.
Gustavo BaldassoDepartment of Veterinary Medicine, School of Life and Sciences, Pontifícia Universidade Católica do Paraná, 1155 Imaculada Conceição Street, Curitiba, PR, 80215-901, Brazil.
Louise Helene BacherDepartment of Veterinary Medicine, School of Life and Sciences, Pontifícia Universidade Católica do Paraná, 1155 Imaculada Conceição Street, Curitiba, PR, 80215-901, Brazil.
Márcio Garcia RibeiroDepartment of Animal Production and Preventive Veterinary Medicine, School of Veterinary Medicine and Animal Sciences, Sao Paulo State University-UNESP, Botucatu, SP, 18618-681, Brazil.
Marconi Rodrigues de FariasDepartment of Veterinary Medicine, School of Life and Sciences, Pontifícia Universidade Católica do Paraná, 1155 Imaculada Conceição Street, Curitiba, PR, 80215-901, Brazil.
Pontifícia Universidade Católica do Paraná · BRMedical University of Warsaw · PLUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProtothecosis is a rare infectious disease caused by unicellular, achlorophyllous, microalgae of the genus Prototheca, ubiquitously distributed in nature. The algae are emerging pathogens, whose incidence is increasing in both human and animal populations and serious systemic infections related to this pathogen have been increasingly described in humans in recent years. After mastitis in dairy cows, canine protothecosis is the second most prevalent form of the protothecal disease in animals. Here, we report the first case of chronic cutaneous protothecosis due to P. wickerhamii in a dog in Brazil, successfully treated with a long-term therapy with itraconazole in pulse. CASE PRESENTATION: Upon clinical examination, exudative nasolabial plaque, ulcered, and painful lesions in central and digital pads and lymphadenitis were observed in a 2-year-old mixed-breed dog, with a 4-month history of cutaneous lesions and contact with sewage water. Histopathological examination revealed intense inflammatory reaction, with numerous spherical to oval, encapsulated structures stained with Periodic Acid Schiff, compatible with Prototheca morphology. Tissue culture on Sabouraud agar revealed yeast-like, greyish-white colonies after 48 h of incubation. The isolate was subjected to mass spectrometry profiling and PCR-sequencing of the mitochondrial cytochrome b (CYTB) gene marker, leading to identification of the pathogen as P. wickerhamii. The dog was initially treated with oral itraconazole at a dosage of 10 mg/kg once daily. After six months, the lesions resolved completely, yet recurred shortly after cessation of therapy. The dog was then treated with terbinafine at a dose of 30 mg/kg, once daily for 3 months, with no success. The resolution of clinical signs, with no recurrence over a 36-months follow-up period, was achieved after 3 months of treatment with itraconazole (20 mg/kg) in pulse intermittently on two consecutive days a week.

conclusionsThis report highlights the refractoriness of skin infections by Prototheca wickerhamii with therapies proposed in the literature and suggests a new treatment option with oral itraconazole in pulse dosing for long-term disease control successfully performed in a dog with skin lesions.

Indexed as

Cattle DiseasesDog DiseasesInfectionsProtothecaSkin Diseases, InfectiousAnimalsCattleDogsFemaleHumansItraconazolePlant BreedingItraconazoleCYTB geneGenetic identificationMALDI-TOF MSPrototheca sp.Prototheca wickerhamii

Identifiers

PMID36810141
PMCPMC9945405
OpenAlexW4321611713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.